This section is intended for UK healthcare professionals. If you are a member of the public click here. If you have been prescribed ADCETRIS click here.

Patients who respond to ADCETRIS have the potential to respond again1

Data were collected from 21 R/R HL patients retreated with ADCETRIS*1

  • Median PFS = 9.9 months
  • Median OS = not reached
  • Median DOR
    • OR patients = 9.2 months
    • CR patients = 9.4 months
  • 45% of CR patients (including HL / sALCL) achieved median duration of response of >1 year
    • 2 subsequently received allogeneic stem cell transplant

Study details

Objective response rate*
Objective response rate

* Included patients who previously achieved a CR or PR with ADCETRIS

**1 patient had no post-baseline response assessment

Adapted from Bartlett et al, 2014.

Reuse with ADCETRIS provides tumour reduction in 79% of HL patients1

Maximum reduction in target lesion size
Maximum reduction in target lesion size

*Tumour reduction measurement available for 19 patients

Adapted from Bartlett et al. 2014

ADCETRIS has a generally manageable toxicity profile1,2

Treatment-emergent adverse events occurring in ≥20% of R/R HL patients (n=21) in this study3

n (%)
Any event2 20 (95)
Peripheral sensory neuropathy 12 (57)
Nausea 9 (43)
Diarrhoea 9 (43)
Fatigue 11 (52)
Headache 6 (29)
Peripheral motor neuropathy 6 (29)
Arthralgia 7 (33)
Dyspnoea 7 (33)
Pyrexia 7 (33)
Anaemia 6 (29)
Back pain 5 (24)
Cough 5 (24)
Dizziness 5 (24)

With the exception of higher incidence of peripheral motor neuropathy (29% total versus 11%) the rates of AEs were consistent with those observed in the pivotal phase 2 trial in R/R HL1,3

Study details


Please use the following link to access the CDF criteria for reuse

Please refer to the guidance in your local NHS service for further information on funding.

Adverse events should be reported. In the United Kingdom, reporting forms and information can be found at

Adverse events should also be reported to Takeda on 01628 537900 or e-mail